Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 25, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.

S Pospisilova1, D Gonzalez, J Malcikova

  • 1Central European Institute of Technology, Masaryk University, Czech Republic.

Leukemia
|February 3, 2012
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.

American journal of hematology·2024
Same author

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.

Blood cancer journal·2023
Same author

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.

Blood·2022
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Search for physics beyond the standard model in events with jets and two same-sign or at least three charged leptons in proton-proton collisions at <math> </math>.

The European physical journal. C, Particles and fields·2020

TP53 mutation is a key prognostic factor in chronic lymphocytic leukemia (CLL), impacting treatment response and survival. Testing for TP53 mutations is crucial for guiding patient management and considering advanced therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Background:

  • TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL), alongside 17p deletion.
  • Approximately 5% of untreated CLL patients requiring treatment harbor TP53 mutations without 17p deletion.
  • These patients exhibit poor response and reduced survival with standard therapies.

Purpose of the Study:

  • To highlight the prognostic significance of TP53 mutations in CLL.
  • To advocate for the integration of TP53 mutation testing into routine CLL diagnostics.
  • To provide guidance on TP53 mutation detection methods and interpretation.

Main Methods:

  • Review of evidence from retrospective analyses and prospective clinical trials.
  • Discussion of various TP53 mutation detection assays, recommending Sanger sequencing for certain settings.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

Related Experiment Videos

Last Updated: May 25, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

  • Development of recommendations for standard operating procedures, quality control, reporting, and interpretation.

    • Main Results:

    • TP53-mutated CLL patients without 17p deletion show inferior outcomes with standard treatments.
    • Sanger sequencing of TP53 exons 4-9 is a viable method for mutation detection.
    • Specific management strategies, including allogeneic stem cell transplantation and clinical trials, are suggested for these patients.

    Conclusions:

    • TP53 mutation testing should be incorporated into the diagnostic workup for CLL patients.
    • Patients with TP53 mutations may benefit from intensified treatment approaches, including stem cell transplantation or novel agents.
    • Further research and clinical trials are essential for optimizing treatment for TP53-mutated CLL.